Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Reassuring Data on Cancer Risk with Contemporary RA Drugs

Reuters Staff  |  September 20, 2017

NEW YORK (Reuters Health)—A large Swedish study1 provides reassuring data on the risk of cancer in patients with rheumatoid arthritis (RA) treated with tumor necrosis factor (TNF) inhibitors or with tocilizumab, abatacept or rituximab. Overall, the risk of malignant neoplasms did not differ between patients treated with a first anti-TNF drug; a second anti-TNF drug; tocilizumab,…

Pfizer Files Suit Against J and J over Remicade Contracts

Caroline Humer  |  September 20, 2017

(Reuters)—Drugmaker Pfizer Inc on Wednesday filed a lawsuit against Johnson and Johnson, saying its rival’s contracts with health insurers for blockbuster rheumatoid arthritis drug, Remicade, were anticompetitive and blocked sales of Pfizer’s new biosimilar. Pfizer said in the suit that Johnson and Johnson is offering discounts on its Remicade treatment in exchange for essentially excluding…

Unbudgeted: How the Opioid Crisis Is Blowing a Hole in Small-Town America’s Finances

Paula Seligson & Tim Reid  |  September 20, 2017

INDIANA, Pa./CHILLICOTHE, Ohio (Reuters)—As deaths mount in America’s opioid crisis, communities on the front lines face a hidden toll: the financial cost. Ross County, a largely rural region of 77,000 people an hour south of Columbus, Ohio, is wrestling with an explosion in opioid-related deaths—44 last year compared with 19 in 2009. The drug addiction…

U.S. Democrats Urge Full Review Before Senate Vote on Latest Obamacare Attack

Susan Cornwell  |  September 20, 2017

WASHINGTON (Reuters)—Democratic leaders in the U.S. Congress on Monday demanded that lawmakers wait to find out the budgetary and healthcare impacts of a new, last-ditch legislative effort by Republicans to repeal Obamacare before voting on it. In their long-running war on former President Barack Obama’s signature healthcare law, Senate Republicans are now proposing to replace…

Poor Sleep Associated with Higher Risk of Chronic Pain

Carolyn Crist  |  September 20, 2017

(Reuters Health)—People who sleep poorly may be more likely to develop a chronic pain condition and have worse physical health, a study from the U.K. suggests. A general decline in both the quantity and quality of hours slept led to a two- to three-fold increase in pain problems over time, researchers found. “Sleep and pain…

Rheumatology Advocates Visit D.C. to Act for Arthritis

From the College  |  September 20, 2017

The ACR/ARHP’s annual fly-in to D.C. (#Act4Arthritis) was a huge success. More than 100 ACR/ARHP members and patients from across the nation attended meetings on Capitol Hill to advocate for people living with rheumatic diseases. In all, our advocates visited 138 Senate and House offices. This year’s fly-in on Sept. 25–26 coincided with the second-annual…

CMS Implements Part B Modifiers for Biosimilars

From the College  |  September 20, 2017

With the advent of biosimilars to the marketplace, the Centers for Medicare and Medicaid Services (CMS) now requires modifiers to identify the manufacturer of a biosimilar/biological product on Part B claims. Modifiers were put in place to provide the CMS with the necessary data needed to track claims payments, as well as the ability to…

RISE Data Use to Be Highlighted at 2017 ACR/ARHP Annual Meeting

Kelly Tyrrell  |  September 20, 2017

This year’s ACR/ARHP Annual Meeting, which takes place Nov. 3–8 in San Diego, features several opportunities to learn more about the ACR’s Rheumatology Informatics System for Effectiveness (RISE) Registry, and the data and tools it offers rheumatologists. For the first time, RISE data will be presented at the Annual Meeting by rheumatologists outside of the ACR’s…

Rheumatology Coding Corner Answer: New Patient Prolonged Service Without Direct Patient Contact, Part 1

From the College  |  September 19, 2017

Take the Challenge. ICD-10 Codes R76.1—Raised antibody titer L20.8—Other atopic dermatitis R20.2—Paresthesia of skin R20.1—Hypoesthesia of skin CPT Codes 99358 and 99359 Rationale The Centers for Medicare & Medicaid Services (CMS) typically does not allow separate payment for physician services that do not require face-to-face time with a patient, but as of Jan. 1, 2017,…

Clinical Thought Process for Proper Medical Decision Making, Part 2

From the College  |  September 19, 2017

In Part 1 of this series, we covered the vital role of medical decision making in determining the final level to bill for a patient encounter. Medical decision making is the key component in coding because it reflects the intensity of the provider’s cognitive labor. This implies that there’s an unseen component involved in the…

  • « Previous Page
  • 1
  • …
  • 396
  • 397
  • 398
  • 399
  • 400
  • …
  • 816
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences